U.S. Pharma Stock News

H2O America stock: overview and recent performance H2O America (HTO) has drawn fresh attention after its recent name change from SJW Group in May 2025. This has prompted investors to reassess how the stock’s returns and fundamentals stack up today. The utility provider, focused on water and related services in the United States, recently closed at $57.32. Over the past month the stock shows a return of a 3.1% decline, while the past 3 months reflect an 8.8% gain and the year-to-date figure...

This article examines whether Intuit, trading at around US$406.99, is currently priced for opportunity or already reflects its strengths, and explains what the current valuation may be indicating. The stock has returned 4.4% over the last 7 days, while the 1-year return shows a 35.1% decline, which can influence how investors think about both upside potential and risk. Recent coverage has focused on how Intuit is positioning its core software platforms and product ecosystem, providing useful...

This article looks at whether Novavax, trading at around US$8.03, is attractively priced or potentially a value trap, by exploring what the current price may be implying about the stock. The stock has seen mixed returns, with a 0.5% decline over the last 7 days, a 4.3% gain over 30 days, 12.6% year to date, 28.1% over 1 year, 7.8% over 3 years and a 95.0% loss over 5 years. Recent headlines around Novavax have kept the stock in focus, particularly as investors reassess its prospects beyond...

In April 2026, Viavi Solutions Inc. reported third-quarter 2026 sales of US$406.8 million, up from US$284.8 million a year earlier, but quarterly net income fell to US$6.4 million and nine‑month results showed a net loss of US$63.1 million despite revenue rising to US$1.08 billion. Alongside this mixed profitability picture, Viavi issued fourth‑quarter 2026 revenue guidance of US$427 million to US$437 million, underscoring management’s confidence that recent acquisitions and data‑center...

Accenture (NYSE:ACN) has invested in conversational AI platform Netomi to expand its use of agentic AI in customer experience. The company has also broadened its AI partnership with Google Cloud to build and deploy industry specific AI agents at scale. These moves aim to embed next generation AI directly into client operations and redefine how enterprises manage customer interactions. Accenture is trading at $180.12, with the stock showing a 1.8% gain over the past week but declines of...

The United States market remained flat over the last week, yet it has seen a significant rise of 28% over the past year, with earnings expected to grow by 16% annually. In this environment, identifying high growth tech stocks involves looking for companies that demonstrate strong innovation potential and robust financial health to capitalize on these favorable conditions.

Over the last 7 days, the United States market has remained flat, yet it has seen a significant rise of 28% over the past year, with earnings projected to grow by 16% annually in the coming years. In such an environment, identifying stocks that are trading below their intrinsic value can offer potential opportunities for investors seeking to capitalize on undervaluation.

The United States market remained flat over the last week, yet it has experienced a significant 28% rise over the past 12 months with earnings projected to grow by 16% annually. In this environment, growth companies with high insider ownership can be particularly appealing as they often indicate strong confidence from those who know the business best.

The market remained flat over the last week, though it has risen 28% over the past year with earnings expected to grow by 16% annually. For investors willing to explore beyond well-known names, penny stocks—often representing smaller or newer companies—can still offer surprising value and potential for growth. In this article, we examine three penny stocks that combine financial strength with promising prospects in today's evolving market landscape.

Over the last 7 days, the United States market has remained flat, yet it is up 28% over the past year with earnings forecasted to grow by 16% annually. In this dynamic environment, identifying stocks that are not only resilient but also poised for growth can uncover potential opportunities in lesser-known companies.

Over the last 7 days, the United States market has remained flat, yet it has experienced a substantial 28% rise over the past year. In this context of expected earnings growth of 16% per annum in the coming years, identifying dividend stocks that offer consistent payouts and potential for capital appreciation becomes crucial for investors seeking stability and income.

In April 2026, Snowflake announced extensive updates to Snowflake Intelligence and Cortex Code, aiming to connect more enterprise data sources, systems, and AI models into a single environment so organizations can run AI agents directly on governed data reflecting how their businesses operate. By positioning these AI agents as a control plane for enterprise workflows and extending Cortex Code across third-party platforms like AWS Glue, Databricks, and Postgres, Snowflake is trying to embed...

First quarter earnings as a fresh signal for Avista stock Avista (AVA) stock is back in focus after first quarter 2026 results showed revenue of US$570 million versus US$617 million a year earlier, while net income reached US$92 million and earnings per share from continuing operations came in at US$1.11. See our latest analysis for Avista. At a share price of US$40.56, Avista has had a 4.75% year to date share price return, while the 1 year total shareholder return is 1.59%. This hints at...

Why Knife River’s latest earnings matter for shareholders Knife River (KNF) reported first quarter revenue of US$410.1 million and a net loss of US$79.2 million, a combination that often prompts investors to reassess how the stock reflects the underlying business. See our latest analysis for Knife River. The earnings update and the recent disclosure that Vanguard Capital Management holds 5.25% of Knife River appear to sit alongside strong recent momentum, with a 30 day share price return of...

Herc Holdings Inc. has already reported first-quarter 2026 results, with sales rising to US$981 million and total revenue to US$1.14 billion, while net loss widened to US$24 million as the company completed integrating H&E Equipment Services and expanded its branch network by 30%. Alongside double-digit specialty revenue growth, record e-commerce revenue, insider share purchases and continued analyst support highlight growing confidence in Herc’s ability to capture benefits from its enlarged...

Inter & Co. Inc. recently attracted attention after analysts projected higher year-over-year earnings and revenue for the March 2026 quarter, with Zacks highlighting an Earnings ESP of 14.00% and a Rank of #2 based on its latest estimate revisions. An interesting angle is that this optimistic earnings setup, centered on expectations of beating consensus EPS, is emerging even as the broader analyst community had already built in ambitious multi-year growth and profitability assumptions for...

Ultra Clean Holdings recently reported first-quarter 2026 results, with revenue rising to US$533.7 million while posting a net loss of US$17.9 million, and concurrently announced the upcoming retirement of CFO Sheri Savage alongside a change in board chair later this month. The company also issued second-quarter guidance calling for higher revenue and a return to GAAP profitability and disclosed new insider trading plans and a Form 144 filing, adding fresh context to its capital structure...

Immunome has submitted a New Drug Application to the FDA for varegacestat, an oral once-daily gamma secretase inhibitor for adults with desmoid tumors, backed by a global Phase 3 RINGSIDE trial that met its primary and key secondary endpoints. A key insight is that RINGSIDE is the largest randomized study conducted in this rare tumor type, with data selected for oral presentation at the 2026 ASCO Annual Meeting, highlighting the clinical community’s interest in varegacestat’s profile. We’ll...

In recent months, multiple law firms have filed securities class action lawsuits against monday.com Ltd., alleging that between September 17, 2025 and February 6, 2026 the company misled investors about its revenue growth outlook, AI-driven expansion, and longer enterprise sales cycles, following reduced guidance and the withdrawal of a previously announced US$1.80 billion 2027 revenue target. These lawsuits raise questions about the transparency and reliability of monday.com’s prior growth...

Las Vegas Sands stock under pressure Las Vegas Sands (LVS) has been under pressure recently, with the stock showing a decline of about 5% over the past month and about 9% over the past three months, prompting investors to reassess expectations. See our latest analysis for Las Vegas Sands. At a share price of $51.86, Las Vegas Sands has seen weaker recent momentum, with a 7 day share price return of 4.79% and a year to date share price return of 20.47%, while the 1 year total shareholder...

L3Harris Technologies (LHX) has drawn fresh attention after reporting first quarter 2026 earnings, with sales of US$5,744 million, higher net income, and raised full year revenue and earnings guidance supported by a record defense backlog. See our latest analysis for L3Harris Technologies. The solid first quarter and raised guidance come after a softer patch in the share price, with a 30-day share price return decline of 13.31% and a 90-day share price return decline of 12.22%, while the...

Recent performance snapshot LGI Homes (LGIH) has moved sharply in recent months, with the stock showing a one month gain of 17.7%, a past 3 months decline of 16.7%, and a 1 year total return decline of 19.8%. See our latest analysis for LGI Homes. At a share price of $44.88, LGI Homes has seen momentum fade recently, with a 1 day share price decline of 7.5% following a 30 day share price gain of 17.7%. The 1 year total shareholder return remains down 19.8%, which points to a stock still...

Trevi Therapeutics recently announced plans to present detailed Phase 2b CORAL trial results and additional nalbuphine ER data for IPF-related chronic cough at the ATS 2026 International Conference in Orlando on May 18, 2026. Alongside upcoming Q1 2026 results and a proposal to double authorized common shares, these scientific disclosures highlight how clinical and corporate actions may shape Trevi’s future options for funding and advancing Haduvio. We’ll now examine how the upcoming Phase...

What Alexander's latest earnings mean for investors Alexander's (ALX) stock was in focus after the REIT reported weaker first quarter results, with lower net income, softer earnings per share, and funds from operations that did not meet analyst expectations. See our latest analysis for Alexander's. Despite the weaker quarter, Alexander's share price has a year to date return of 11.4% and the 1 year total shareholder return of 24.16% suggests momentum has been building over a longer...